Show simple item record

dc.contributor.advisorSalinas, Santiago
dc.contributor.advisorLaLonde, Jennifer
dc.contributor.authorWashington, Lesli
dc.date.accessioned2019-04-06T16:02:55Z
dc.date.available2019-04-06T16:02:55Z
dc.date.issued2019
dc.identifier.urihttp://hdl.handle.net/10920/36758
dc.descriptioniv, 29 p.en_US
dc.description.abstractOther than dialysis and renal replacement therapies, there is currently no cure or concrete means of prevention for acute kidney injury (AKI) Currently, renal research is looking for better prognoses and diagnoses of AKI with one area of research being focused on AKI specific biomarkers Biomarker levels in laboratory reports from patients enrolled into Quark Pharmaceuticals began, “A Randomized, Double-Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery” were analyzed Patients were defined as either AKI or non-AKI according to RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) and the Acute Kidney Injury Network (AKIN) classifications Grubb’s test was used to see if AKI patient(s) abnormal biomarker level(s), outside normal reference ranges, had an increased possibility of causing the AKI classifying event Data analysis was done on visits Baseline/-1, day prior to patient(s) AKI classifying event, and day of patient(s) AKI classifying event Results showed, that one patient classified as AKI by definition On the same day as their AKI classifying event, they had one statistically significant abnormal biomarker, magnesium, that in conclusion may have increased the possibility of the AKI classifying event There were many limitations to this study including: small sample size, double-blinding of clinical trial study drug QPI-1002, and limited knowledge on patient medical history or medical interventions However, this study still conveys broader implications about the importance of biomarker research for better diagnoses and prognoses of AKI to help decrease a worldwide health problem and increase individual patients’ quality of life.en_US
dc.format.mimetypeapplication/pdf
dc.language.isoen_USen_US
dc.publisherKalamazoo Collegeen_US
dc.relation.ispartofKalamazoo College Biology Senior Individualized Projects Collection
dc.rightsU.S. copyright laws protect this material. Commercial use or distribution of this material is not permitted without prior written permission of the copyright holder.
dc.titleSearch for Significant Biomarkers Associated with Acute Kidney Injury (AKI) in Patients Enrolled into a Double-blinded Phase III Clinical Trial for Prevention of AKI following Cardiac Surgery with siRNA Study Drug QPI-1002en_US
dc.typeThesisen_US
KCollege.Access.ContactIf you are not a current Kalamazoo College student, faculty, or staff member, email dspace@kzoo.edu to request access to this thesis.


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • Biology Senior Individualized Projects [1520]
    This collection includes Senior Individualized Projects (SIP's) completed in the Biology Department. Abstracts are generally available to the public, but PDF files are available only to current Kalamazoo College students, faculty, and staff.

Show simple item record